Early development evaluation of AZD8081: a substrate for the NK receptors
Artikel i vetenskaplig tidskrift, 2011

The purpose of the present study was to find out if AZD8081, a dual neurokinin (NK)1/2 receptor antagonist, was suitable for development of an oral, solid immediate release (IR) formulation and in a further perspective also as an oral extended release (ER) formulation. AZD8081 is a base with pK(a) values <2.5 and about 8.5. The measured intrinsic solubility is about 0.1 mg/mL and the solubility in FaSSIF (fasted simulated small intestinal fluid) is about 3.2 mg/mL. Aqueous buffer solutions are stable for at least 1 month between pH 1-7 up to 37 degrees C. In the solid-state, a mixture of amorphous and crystalline substance showed significant chemical instability in the initial stress testing studies. No degradation was, however, observed for highly crystalline material at similar conditions. It is concluded that the impurity profile and/or the present solid-state of the batches affect the stability of the substance. The amorphous contribution of the substance is the main cause to the observed degradation in solid-state. Crystalline AZD8081 is polymorphic with two known monotropic forms, form A and form B. Both forms are only slightly hygroscopic ansolvates with melting points of approximately 108 degrees C and 117 degrees C, respectively. Form B is the more stable of the two forms and is therefore most suited for further development. The candidate is suitable for development of standard IR formulations since no specific limitations of significance for formulation development were identified. In addition, the good stability in human intestinal fluid and in colon slurry makes AZD8081 a suitable candidate for ER formulation.

NK receptor

preformulation

bioavailability

binding-sites

dissolution

IBS

rat-brain

Drug development

peripheral tachykinin receptors

dosage forms

classification

antagonists

absorption

drug delivery

stability

express substance-p

Författare

Kalle Sigfridsson

Chalmers, Kemi- och bioteknik

M. Ahlqvist

AstraZeneca AB

A. Carlsson

AstraZeneca AB

A. Fridstrom

AstraZeneca AB

Drug Development and Industrial Pharmacy

0363-9045 (ISSN) 1520-5762 (eISSN)

Vol. 37 6 702-713

Ämneskategorier

Farmaceutisk vetenskap

DOI

10.3109/03639045.2010.535823